Gloria Snepp

In 1937, at just 19 years old, Gertrude Belle Elion graduated summa cum laude in chemistry from Hunter College. Despite her outstanding academic record, she was rejected by all 15 graduate schools she applied to — simply because she was a woman. Laboratories at the time openly refused to hire or fund female researchers. Motivated by the painful loss of her grandfather to cancer, Elion refused to give up. During World War II, she joined Burroughs Wellcome (now part of GSK), where she collaborated with George Hitchings to pioneer a revolutionary approach called rational drug design. Instead of relying on trial and error, they studied the biochemistry of diseased cells to create targeted, precision medicines. When forced to choose between pursuing a traditional PhD or continuing her groundbreaking laboratory work, Elion chose the lab. She never earned a doctorate during her career. Her persistence paid off in ways that transformed human health. Elion developed: · 6-mercaptopurine (6-MP) — the first effective treatment for childhood leukemia · Azathioprine (Imuran) — which made organ transplantation possible by suppressing immune rejection · Acyclovir (Zovirax) — the first selective antiviral drug, proving viruses could be targeted specifically Her research also laid the foundation for early HIV treatments. In 1988, Elion was awarded the Nobel Prize in Physiology or Medicine (shared with Hitchings and Sir James Black), becoming one of the few Nobel laureates to receive the honor without a PhD. Gertrude Elion’s story is a powerful reminder that brilliance and determination can overcome systemic barriers — and one person’s refusal to be stopped can save millions of lives.